B
Blue Note Therapeutics
Blue Note Therapeutics | Helping Cancer Patients Live Better
About Blue Note Therapeutics
Blue Note Therapeutics develops clinically validated prescription digital therapeutics aimed at reducing anxiety, depression, and other distress related to cancer. The company collaborates with leading cancer centers, community oncology clinics, and patient teams to create solutions that serve all cancer patients, from early-stage through survivorship, in both inpatient and outpatient settings. Blue Note's business model focuses on providing oncology-specific mental health care through digital platforms, partnering with organizations like the National Comprehensive Cancer Network (NCCN) to ensure the highest standards of care. Revenue is generated through the development and distribution of FDA-approved digital devices and applications designed to improve the emotional well-being of cancer patients. The company also offers free wellness apps, such as Attune OTC, to specific communities, including Spanish-speaking patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 34.6/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Psychology, Oncology, Digital Therapeutics, Hard Tech
- Technology
- Mobile app
- Business model
- SaaS
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2021 | $5.2M | $131M | JAZZ Venture Partners · Alumni Ventures · Summer VC · Memorial Sloan - Kettering Cancer Center | — |
| SERIES A✓Equity / VC | Mar 2021 | $26M | $105M | JAZZ Venture Partners · Summer VC | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Blue Note Therapeutics is 190 monthly website visits, down 62% over the last three months. Blue Note Therapeutics's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- JPJAZZ Venture Partners
Summer VC
Alumni Ventures
Memorial Sloan - Kettering Cancer Center
Other known investors1 additional known investor
For Good Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Blue Note Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Blue Note Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.